Update your tester profile Login
  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies. We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

  • Diagnosed with Liver Impairment?

    Prism Research has upcoming studies for individuals diagnosed with liver impairment.  These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of liver impairment when compared to volunteers with normal liver function.

     

    If you or someone you know has been diagnosed with liver impairment and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Financial compensation is provided for study participation time.

  • Study 1620: Male and Female Participants with Nasal Polyps

    Research Purpose: Study 1620 is designed to determine the safety and tolerability of an investigational drug being developed for the treatment of Chronic Rhinosinusitis with Nasal Polyps.

    *Must be diagnosed with Nasal Polyps to participate in this study*

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women may participate if they meet one of the following criteria: postmenopausal, hysterectomy and/or bilateral oophorectomy, medically confirmed ovarian failure, tubal ligation or bilateral salpingectomy.

    Age

    18-65 years

    Body Mass Index (BMI)

    Between 17.5 – 35.0 kg/m²

    Tobacco/Nicotine Use

    Must be willing to abstain from tobacco and/or nicotine containing products for 24 hours prior to dosing and during the clinic stay.

    Health History

    Must be healthy; with the exception of diagnosed nasal polyps and chronic rhinosinusitis.

    Restricted Medications

    All medications will be reviewed for inclusion prior to screening.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 12 months.

    Clinic Stay

    • Participants will admit to Prism Clinical Research one-time for 2 overnights

    Clinic Visits

    • There are up to 13 follow-up clinical visits

     

    Compensation for participation time:   Up to $1,860                           


    For information regarding this study contact Dayna 651-724-5047 or daynas@prismresearchinc.com

  • Study 1701: Healthy Male and Female Participants

    Research Purpose: Study 1701 is designed to evaluate how one drug interacts with the investigational drug being developed for the treatment of malignant diseases.

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women of non-childbearing potential will be allowed to participate.

    Age

    18-55 years

    Body Mass Index (BMI)

    Between 18-32 kg/m²

    Tobacco/Nicotine Use

    No more than 5 cigarettes/week or its nicotine or tobacco equivalent in the 2 months prior to screen.  No smoking during your clinic stays.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions

    Restricted Medications

    No prescription, nonprescription drugs, dietary supplements, vitamins or herbal preparations 7 days prior to the start of the study through the final study visit unless approved by the study doctor

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 4 weeks.

    Clinic Stay

    • Participants will be confined at Prism Clinical Research two separate times during a 21 day period
    • The first Clinic stay will last approximately 10 days (9 overnights)
    • The second Clinic stay will last approximately 3 days (2 overnights)

    Return Clinic Visits

    • There is one Return Clinic visit approximately 2 weeks following the final discharge from the clinic.

     

     

    Screenings begin:February 28th

    Anticipated start date for Study 1701: March 23rd

     

    Compensation for participation time:   Up to $2,825.00

                           

    For information regarding this study contact Andy: 651-724-8399 or andyh@prismresearchinc.com

  • Study 1703:Healthy Participants Who Have Experienced episodes of cold sores due to Herpes Simplex Virus Type 1 infection

    Research Purpose: Study 1703 is a study to evaluate immune response in subjects infected with Herpes Simplex Virus Type 1 (HSV-1).

     *Must have experienced episodes of cold sores due to HSV-1 *

     Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not pregnant or breastfeeding are allowed to participate.  Women of childbearing potential must agree to use approved birth control while in the study and for a period of one month after study completion.

    Age

    18-64 years

    Body Mass Index (BMI)

    Between 18-35 kg/m²

    Tobacco/Nicotine Use

    Nicotine use is permitted

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    Therapy with glucocorticoid or immunosuppressants 4 weeks prior to screening or anti-viral therapy any time in the past 12 months

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 12 weeks.

    In-clinic Stay

    • There are no in-clinic stays required for this study

    Out-clinic Visits Group A

    • There is one screening visit and 3 visits at the clinic

    Out-clinic Visits Groups B and C

    • There is one screening visit and one visit at the clinic

    Compensation for participation time:   Group A up to $340.00; Groups B & C up to $170.00

                           

    For information regarding this study contact Kevin: 651-724-5046

    email: kfitzgerald@prismresearchinc.com

    Dayna: 651-724-5047 or daynas@prismresearchinc.com

  • Study 1702: Participants with Reduced Liver Function

    Research Purpose: Study 1702 is designed to evaluate bacteria in the digestive system and different methods of stool sample collection. No investigational drug will be administered. Participants will collect 6 stool samples from 4 different bowel movements over the course of 10 days.

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate

    Age

    18-75 years

     

    Study Time Commitment: Study participation will last for approximately 10 days.

    Outpatient Visits

    • There are a total of 3 outpatient visits including screen

     

    Compensation for participation time:   Up to $410.00

                                   

    For information regarding this study contact Dayna at 651-724-5047 or email daynas@prismresearchinc.com

Recruitment and Volunteer Demographics

Prism Clinical Research recognizes the need to continually grow our diverse volunteer database populations. Through a multi-faceted enrollment process that includes a dedicated recruitment department, collaborative physician partnerships, advertising and subject referral programs, Prism Clinical Research can deliver Phase I-II results in the following populations:

  • HIV

  • Hepatic

  • Renal (Pre-ESRD, ESRD)

  • Type 2 Diabetes

  • Obesity

  • Healthy Male/Female/Elderly

  • Gilbert’s subset

  • Rheumatoid Arthritis

  • Epilepsy

  • Multiple Sclerosis
  • GI (IBS & Crohn’s)

  • Celiac
  • COPD, Allergy and Asthma

  • High Cholesterol

  • Hypertensive

  • Alzheimer's Disease
  • Ophthalmology

  • Slow Metabolizers

  • Osteoporosis
  • Osteoarthritis
  • Lupus

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel